



# The somatotrophic axis and aging: Benefits of endocrine defects



Andrzej Bartke<sup>a,\*</sup>, Edward O. List<sup>b,c</sup>, John J. Kopchick<sup>b,c</sup>

<sup>a</sup> SIU School of Medicine, Department of Internal Medicine, 801 N. Rutledge, P.O. Box 19628, Springfield, IL 62794-9628, United States

<sup>b</sup> Edison Biotechnology Institute, Ohio University, Athens, OH 45701, United States

<sup>c</sup> Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, United States

## ARTICLE INFO

### Article history:

Received 18 September 2015

Received in revised form 27 January 2016

Accepted 12 February 2016

Available online 16 February 2016

### Keywords:

Growth hormone

Growth hormone receptors

Longevity

IGF-1

Liver

Muscle

Adipose tissue

## ABSTRACT

Reduced somatotrophic [growth hormone (GH) and insulin-like growth factor-1 (IGF-1)] action has been associated with delayed and slower aging, reduced risk of frailty, reduced age-related disease and functional decline, and with remarkably extended longevity. Recent studies have added to the evidence that these relationships discovered in laboratory populations of mice apply to other mammalian species. However, the relationship of the somatotrophic signaling to human aging is less striking, complex and controversial. In mice, targeted deletion of GH receptors (GHR) in the liver, muscle or adipose tissue affected multiple metabolic parameters but failed to reproduce the effects of global GHR deletion on longevity. Continued search for mechanisms of extended longevity in animals with GH deficiency or resistance focused attention on different pathways of mechanistic target of rapamycin (mTOR), energy metabolism, regulation of local IGF-1 levels and resistance to high-fat diet (HFD).

© 2016 Elsevier Ltd. All rights reserved.

## 1. Introduction

Research findings reported during the last 20 years have provided numerous examples of remarkably extended longevity in mice with hereditary defects in somatotrophic (GH/IGF-1) action [1–3]. Importantly, in both GH-resistant (GHRKO) and GH-deficient [hypopituitary Ames dwarf (Prop1<sup>df</sup>) and Snell dwarf (Pit1<sup>dw</sup>)] mice, extension of average, median and maximal longevity is associated with improved maintenance of physical and cognitive function, resistance to oxidative stress, as well as reduced incidence and/or delayed onset of neoplasms and other age-related pathologies [4–6]. Trade-offs include major decreases in growth rate and adult body size, delayed maturation and reduced fertility [4–7] which appears to be partially offset by a delay in reproductive aging [8,9].

Studies of the relationships among longevity, adult body size, alterations in bone characteristics and polymorphism of genes involved in GH and IGF-1 induced signaling have provided evidence that the somatotrophic axis is involved in the control of aging in other mammalian species, including humans [7,10–13]. Moreover, comparative studies of mutations that affect aging in different organisms uncovered an astonishing degree of homology [14,15], and it is now well established that the evolutionarily conserved insulin/IGF-1 signaling (IIS) pathway has a major role in the control of aging in species ranging from unicellular yeast and microscopic worms to insects and vertebrates [16,17]. GH

has no identified homologs in yeast, worms or flies, but influences IIS as a key stimulator of IGF-1 expression and an important modulator of the secretion and actions of insulin. A recent study suggested that the remarkable differences of lifespan between various mammalian species are also related to somatotrophic action [18].

The role of GH and IIS in the control of mammalian aging and the physiological characteristics of long-lived GH-related mutants were reviewed by us and others [4–7]. In this brief article we will not attempt to provide a comprehensive discussion of these topics, but instead will describe recent findings focusing on the mechanisms linking somatotrophic action and aging and on the studies aimed at identifying the role of GH in different tissues in the control of longevity.

### 1.1. Extended longevity of mice with isolated GH deficiency

Most of the evidence for the role of GH in the control of aging was derived from studies in animals with deficiencies of three adenohypophyseal hormones (GH, prolactin and thyrotropin) or disruption of GH receptors [1–7]. In contrast to findings in these animals, longevity was not affected by transgenic expression of a GH receptor antagonist [19] and the impact of isolated GH deficiency due to mutation of the GH releasing hormone (GHRH) receptor in “little” mice on longevity was relatively modest and dependent on diet composition [2]. Therefore, when Salvatori and his colleagues developed a new line of mice with isolated GH deficiency by disrupting the GHRH gene [20], it was of great interest to examine their aging-related traits and longevity. In both sexes of GHRH-KO

\* Corresponding author.

E-mail address: [abartke@siu.edu](mailto:abartke@siu.edu) (A. Bartke).

mice the median and the maximal longevity were significantly increased [21]. The extension of median longevity was particularly striking: 43% in females and 51% in males. GHRH-KO mice share many phenotypic characteristics with GHRKO and Ames dwarf mice. This includes reductions in IGF-1 levels, body weight, blood glucose, plasma insulin, triglyceride and cholesterol levels and respiratory quotient and increases in adiposity (particularly, subcutaneous fat), plasma leptin and adiponectin levels and insulin sensitivity [21]. However, in contrast to the findings in other GH-related long-lived mutants, glucose tolerance was not altered in the GHRH-KO mice and the trend for increased oxygen consumption per gram of body weight was not significant. Analysis of hepatic gene expression profiles revealed major shifts in the expression of genes related to xenobiotic detoxification and stress resistance with many similarities to previous findings in other GH-related long-lived mutants [21].

### 1.2. Impact of reduced systemic and local IGF-1 signaling on longevity

Preliminary studies in mice in which circulating IGF-1 levels are reduced due to the improper insertion of a null IGF-1 construct in the native IGF-1 allele that allows expression of small amounts of IGF-1, indicated that longevity is extended in females but not in males [22]. A recent report with detailed analysis of longevity in these animals at three different locations revealed significant extension of maximal longevity and reduction of age-specific mortality rates but, surprisingly, no consistent effect on mean lifespan [23]. Phenotypically, these animals exhibited some characteristics resembling long-lived hypopituitary and GH-resistant mice including resistance to the detrimental effects of HFD [24]. However, their insulin resistance was increased rather than reduced [24].

Recent work has also provided new information on the effects of partial IGF-1 resistance on longevity. Longevity of animals heterozygous for the deletion of IGF-1 receptor [IGF-1R(+/-)] was reexamined in the Holzenberger laboratory to address the discrepancy between the major extension of female longevity and a similar trend in males in the original studies in 129/SvPas mice [25] and the very small effect strictly limited to females in C57BL/6 mice examined by Bokov et al. [26]. Results indicated that extension of female longevity in IGF-1R(+/-) animals is reproducible on both genetic backgrounds and that the difference in the magnitude of this effect is likely related to strain differences in the normal levels of activation of the IGF-1 receptor and insulin receptor substrates, IRS1 and IRS2, and in the impact of the loss of one IGF-1R allele on the activation of these IGF-1 targets [27].

Sex dimorphism in the longevity response to partial IGF-1 resistance resembles the findings in IRS-1<sup>-/-</sup> [28] and S6K1 [29] mice in which only females live longer. Differential responses of females and males to genetic or pharmacological age-delaying interventions are not uncommon [30–32] but are difficult to explain. Speculations about the possible mechanisms of these dimorphisms include the possible role of different, often opposite effects of female and male sex hormones on somatotrophic signaling, metabolism and immune function, differences in the impact of diet composition on various classes of immune cells [33] and sex-specific patterns of pulsatile GH release leading to dimorphism of hepatic enzymes involved in detoxification of endogenous and exogenous toxins (xenobiotics) [34,35].

In contrast to the relatively modest effects of reducing the levels of systemic IGF-1 or global IGF-1 receptor levels on longevity, reducing local (tissue) levels of bioavailable IGF-1 by deletion of pregnancy associated plasma protein A (PAPP-A), a protease which degrades IGF-1 binding proteins (particularly IGFBP4), produces robust extension of longevity in both sexes [36]. In addition to extended longevity, PAPP-A-KO mice have delayed incidence and occurrence of neoplasms [37] and are resistant to experimental induction of atherosclerosis and diabetic nephropathy [37] and to the detrimental effects of HFD on body composition and metabolism [37]. Interestingly, GHRKO mice,

Ames dwarf mice and transgenic mice expressing GH receptor antagonist are also relatively insensitive to the detrimental impact of HFD on glucose homeostasis even though this diet further increases their enhanced adiposity [38,39, Hill & Bartke, unpublished].

Reducing circulating IGF-1 levels in adult mice by inducible disruption of the Igf1 gene in the liver induced liver inflammation, accelerated bone loss, oxidative stress in different tissues and increased incidence of hepatic tumors, thus markedly impairing healthspan [40]. This was presumably due to interference with the normal negative feedback of IGF-1 on GH release and the resulting chronic increase in GH levels [40]. In numerous studies in transgenic mice, elevated GH levels have been associated with multiple symptoms of accelerated aging, promotion of tumor development and reduced longevity [41,42].

### 1.3. Selective deletion of the GH receptor in different GH target organs fails to recapitulate the effects of global GH resistance on aging and longevity

GH influences the function of multiple organs via direct and IGF-1 mediated effects as well as multiple secondary mechanisms including changes in body composition and distribution of adipose tissue, alterations in insulin levels and sensitivity and various metabolic adjustments. In an effort to identify local and systemic effects of GH signaling in its various target organs, several laboratories generated mice with targeted deletion of the GH receptor in the liver, muscle, adipose tissue, pancreatic  $\beta$ -cells or macrophages [43–50]. The resulting animals with organ specific GH resistance were phenotypically very different from the GHRKO mice. Thus, mice with deletion of GHR in the liver generated by Fan et al. [43] had impaired glucose homeostasis, liver steatosis and increases in fibrosis and inflammation. Presumably these characteristics represent the net result of reductions in hepatic IGF-1 expression and circulating IGF-1 levels with concomitant increase in GH release due to dampening of the IGF-1 negative feedback.

Mavalli et al. [44] and Vijayakumar et al. [45] used different promoter enhancers (Mef-2c-73 k and muscle creatine kinase, MCK) to drive Cre expression specifically in the muscle in the course of producing mice with muscle-specific GHR deletion. Surprisingly, this resulted in very different, generally opposite alterations in body weight and composition, as well as insulin sensitivity as MCK mice were smaller and leaner with enhanced insulin sensitivity and Mef mice were heavier, with increased adiposity and impaired insulin sensitivity [44,45]. Furthermore, muscle structure and strength were negatively affected in Mef mice, while lipid metabolism and inflammation markers were improved in the MCK mice [44,45]. The reasons for these differences are unclear; however, the findings indicate that interference with GH signaling in only one of its target organs can alter phenotypic characteristics previously associated with aging as putative mechanisms or surrogate markers.

Alterations in metabolic characteristics related to aging were reported also in mice lacking GH receptors in insulin producing cells or macrophages. Disruption of GHR in pancreatic  $\beta$ -cell resulted in impairment of glucose-stimulated insulin secretion, failure of hyperplasia in response to HFD and glucose intolerance in HFD-fed mice [48]. Enhanced susceptibility to the detrimental effects of HFD on glucose homeostasis and inflammation was also seen in mice with deletion of GHR in macrophages [49]. This contrasts with the resistance to the diabetogenic (but, interestingly, not obesogenic) effects of HFD in GHRKO and Ames dwarf mice [39, Hill & Bartke unpublished].

To determine the role of different organs in mediating the striking effects of global GHR deletion on aging and longevity, the Kopchick laboratory produced new lines of mice with deletion of GHR limited to the adipose tissue, liver or skeletal and cardiac muscles [46,47,50]. Growth, body composition, glucose homeostasis and other phenotypic characteristics of animals from each of these lines were unique but none of them reproduced the phenotype of the animals with global GHR deletion (Table 1). However, mice with fat-specific GHR disruption

Download English Version:

<https://daneshyari.com/en/article/2802481>

Download Persian Version:

<https://daneshyari.com/article/2802481>

[Daneshyari.com](https://daneshyari.com)